Full Text View
Tabular View
Study Results
Related Studies
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)
This study has been completed.
Study NCT00863746   Information provided by Bayer

First Received on March 17, 2009.   Last Updated on April 17, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial